Specifically, ATG5 concentrations resulted in being significantly decreased in the temporal cortex of DLB and FTD patients, showing only a downward trend in the AD group, and in the frontal cortex specimens of all patients, with heterogenous values in AD patients. The gene discussed is ATG5; the disease is Alzheimer disease.